DOCSLIB.ORG

Senior Executives

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Senior Executives Senior Executives Mizuho Financial Group Masayuki Hoshi Tsuyoshi Hatsuzawa Managing Executive Officer Managing Executive Officer Directors and Executive Officers, Head of Financial Institutions & Public Sector Deputy Head of Risk Management Group Business Unit / Head of Transaction Banking Unit as defined in the Companies Act Kazuhisa Sawa Yasuhiro Sato Tomoshige Jingu Managing Executive Officer Director, President & Group CEO Managing Executive Officer Deputy Head of Strategic Planning Group / Deputy (Representative Executive Officer) Head of Human Resources Group (Group CHRO) Head of Financial Control & Accounting Group / Deputy Head of IT & Systems Group / Deputy Head Yasunori Tsujita of Operations Group Executive Officers, as defined in Director, Deputy President & Executive Officer Takashi Kamada (Representative Executive Officer) our internal regulations Managing Executive Officer Head of Internal Control (Risk Management, Human Deputy Head of Personal Banking Unit / Deputy Resources and Compliance) and Head of Compliance Masaaki Kono Head of Retail Banking Unit Group (Group CCO) Deputy President & Executive Officer Deputy President (Western Japan (Kinki, Chugoku Ryusuke Aya and Shikoku regions)) Yoshihito Bando Managing Executive Officer Director, Managing Executive Officer Deputy Head of Asset Management Unit Head of Risk Management Group (Group CRO) Katsunobu Motohashi Managing Executive Officer Junichi Shinbo Head of Asset Management Unit Kenichi Minamitani Managing Executive Officer Director, Managing Executive Officer Deputy Head of Compliance Group Head of Financial Control & Accounting Group Hiroshi Suehiro (Group CFO) Managing Executive Officer In charge of Compliance with US FBO Regulation Hideo Gamou Koji Fujiwara Managing Executive Officer Director, Managing Executive Officer Masayuki Yonetani Deputy Head of Asset Management Unit Head of Strategic Planning Group (Group CSO) Managing Executive Officer Head of Corporate Banking Unit Hidefumi Kobayashi Hideyuki Takahashi Managing Executive Officer Director Tetsuhiko Saito Deputy Head of Financial Control & Accounting Managing Executive Officer Group / Deputy Head of Risk Management Group Nobukatsu Funaki Head of Personal Banking Unit / Head of Retail Masahiro Miyamoto Director Banking Unit Managing Executive Officer Akihiko Nomiyama Tatsufumi Sakai Deputy Head of International Banking Unit / Deputy Director (Outside Director) Managing Executive Officer Head of Investment Banking Unit Head of International Banking Unit Mitsuo Ohashi Shuzo Fujii Director (Outside Director) Daisuke Yamada Managing Executive Officer Managing Executive Officer Deputy Head of Corporate Banking Unit Takashi Kawamura Head of Corporate Banking Unit (Large Corporations) Director (Outside Director) Masaya Usuha Takeru Watanabe Managing Executive Officer Tatsuo Kainaka Managing Executive Officer Deputy Head of Operations Group Director (Outside Director) Deputy Head of Personal Banking Unit / Deputy Head of Retail Banking Unit Tatsuya Yamada Kanemitsu Anraku Managing Executive Officer Director (Outside Director) Haruki Nakamura Deputy Head of IT & Systems Group Managing Executive Officer Hiroko Ota Joint Head of IT & Systems Group Tetsuhiro Sakamoto Director (Outside Director) Managing Executive Officer Kazuya Kobayashi Deputy Head of Human Resources Group Toshitsugu Okabe Managing Executive Officer Deputy President & Executive Officer Head of Investment Banking Unit Junichi Yamada Head of Strategic Planning and Management Managing Executive Officer Control (Personal Banking, Retail Banking and Tadashi Ohi Deputy Head of Financial Institutions & Public Sector Corporate Banking) Managing Executive Officer Business Unit / Deputy Head of Markets Unit Deputy Head of Human Resources Group Daisaku Abe Masuo Fukuda Deputy President & Executive Officer Shinya Tanaka Managing Executive Officer Head of IT & Systems Group (Group CIO) / Head of Managing Executive Officer Deputy Head of Corporate Banking Unit (Large Operations Group (Group COO) Deputy Head of Investment Banking Unit Corporations) Tadashi Kanki Masato Monguchi Shinya Hanamura Senior Managing Executive Officer Managing Executive Officer Managing Executive Officer Head of Internal Audit Group (Group CA) Deputy Head of Compliance Group Deputy Head of Financial Institutions & Public Sector Business Unit Akira Sugano Makoto Okayama Senior Managing Executive Officer Managing Executive Officer Kouji Arita Head of Strategic Planning and Management Control Deputy Head of Corporate Banking Unit (Large Executive Officer (International Banking, Investment Banking and Asset Corporations) / Deputy Head of Corporate Banking General Manager of Operations Planning Division Management) Unit / Deputy Head of Financial Institutions & Public Sector Business Unit Akira Nakamura Junichi Kato Executive Officer Managing Executive Officer Nobumitsu Watanabe General Manager of Corporate Banking Head of Markets Unit Managing Executive Officer Coordination Division (Large Corporations) Deputy Head of International Banking Unit / Deputy Head of Investment Banking Unit / Deputy Head of Kouji Yonei Transaction Banking Unit / Deputy Head of Markets Executive Officer Unit General Manager of IT & Systems Planning Division 66 Masahiro Otsuka Hokuto Nakano Yasuo Agemura* Executive Officer Managing Executive Officer Deputy President General Manager of Retail Banking Coordination Division Head of East Asia Head of Global Markets / Head of Markets & Products Division / Head of Global Business & Markets Takahiko Yasuhara Katsuyuki Mizuma Executive Officer Managing Executive Officer Hideo Gamou* General Manager of International Coordination Division Head of Asia & Oceania excl. East Asia Managing Director Head of Asset Management Group Satoshi Ishii Executive Officer Shuichi Shimada* General Manager of Corporate Secretariat / General Mizuho Trust & Banking Managing Director Manager for Executive Secretariat Head of Strategic Planning Group / In charge of Directors Investment Dept. / Attached to Investment Banking Shinji Taniguchi Division Executive Officer Takashi Nonaka General Manager of Investment Banking Chairman Hidefumi Kobayashi* Coordination Division Managing Director Takeo Nakano* Head of Global Finance / Head of Research Group / President & CEO (Representative Director) Head of Finance & Accounting Group / In charge of Mizuho Bank Toshihiko Fukuzawa* Due Diligence Dept. Deputy President (Representative Director) Keizo Ohashi Directors Head of Business promotion Director Nobuhide Hayashi* Tadashi Ohi* Kenji Fujii* President & CEO (Representative Director) Deputy President (Representative Director) Director Head of Human Resources Group and Head of Head of Global Risk Management / Head of Risk Masaaki Kono* Internal Audit Group Management Group Deputy President (Representative Director) Deputy President (Western Japan (Kinki, Chugoku and Masao Yoshikawa* Yasuhiro Sato Shikoku regions)) Deputy President (Representative Director) Director Head of Business promotion Yasunori Tsujita* Hidetaka Kawakita Deputy President Masato Monguchi* Director (Outside Director) Head of Compliance Group Managing Director Head of Compliance Group Masaru Ono Kosuke Nakamura* Director (Outside Director) Deputy President (Representative Director) Tsuyoshi Hatsuzawa* Head of Business Promotion Managing Director Head of Risk Management Group and in charge of Nobuyuki Fujii* Credit Department Notes: 1. *indicates directors concurrently serving as Senior Managing Director (Representative Director) executive officers. Head of Business Promotion Kazuhisa Sawa* 2. The Chairman and the Deputy Chairman of Managing Director the Board of Directors, and the committee Ryusuke Aya* Head of Strategic Planning, Financial Control & members and the Chairman of each Managing Director Accounting Group / Head of IT & Systems Group / Head of Risk Management Group Head of Operations Group / In charge of Executive committee of Mizuho Financial Group are as Secretariat follows: Junichi Shinbo* Chairman of the Board of Directors: Managing Director Yasuhiro Sato Hiroko Ota Head of Financial Control & Accounting Group Director Deputy Chairman of the Board of Koji Fujiwara* Masaru Ono Directors: Hideyuki Takahashi Managing Director Director (Outside Director) Nominating Committee members: Mitsuo Head of Strategic Planning Group Ohashi (Chairman), Takashi Kawamura, Eiji Ogawa Tatsuo Kainaka and Hiroko Ota Hideyuki Takahashi Director (Outside Director) Compensation Committee members: Director Tatsuo Kainaka (Chairman), Akihiko Hirohisa Kashiwazaki Nomiyama, Takashi Kawamura and Director Mizuho Securities Kanemitsu Anraku Audit Committee members: Hideyuki Yasuhiro Sato Directors Takahashi (Chairman), Akihiko Nomiyama, Director Tatsuo Kainaka, Kanemitsu Anraku and Mitsuhiro Nagahama Nobukatsu Funaki Yukio Machida Chairman 3. The corporate auditors and executive officers, Director (Outside Director) Hiroshi Motoyama* excluding the directors concurrently serving Seiji Koga President & CEO (Representative Director) as executive officers and executive officers Director (Outside Director) responsible for global regional operations of Yasuhiko Imaizumi* Mizuho Bank, have not been listed. Deputy President (Representative Director) 4. The corporate auditors and executive officers, Head of Corporate Business Executive Officers excluding the directors concurrently serving (Head of Each Region Overseas) Hajime Saito* as executive officers of Mizuho Trust & Atsushi Narikawa Deputy President Banking and Mizuho Securities, have not
Load more

Recommended publications
  • Country Financial Institutions Swift Rma
    LIST OF RMA EXCHANGED (DANH SÁCH NGÂN HÀNG TRAO ĐỔI RMA) COUNTRY FINANCIAL INSTITUTIONS SWIFT RMA Wells Fargo Bank, N.A, New York International 1 Branch PNBPUS3N 2 Wells Fargo Bank, N.A PNBPUS33 3 Wells Fargo Bank, N.A WFBIUS6W 4 JPMorgan Chase Bank, N.A CHASUS33 5 CitiBank, N.A CITIUS33 6 Woori America Bank HVBKUS3N 7 Woori America Bank, Los Angeles HVBKUS61 8 International Finance Corporate IFCWUS33 United States 9 Industrial & Commercial Bank of China ICBKUS33 10 Shinhan Bank SHBKUS33 11 First Bank FBOLUS6L 12 Bank of Tokyo-Mitsubishi UFJ, LTD, NY Branch BOTKUS33 13 Bank of Tokyo-Mitsubishi UFJ, LTD, Chicago Branch BOTKUS4C Bank of Tokyo-Mitsubishi UFJ, LTD, Los Angeles 14 Branch BOTKUS6L 15 UniCredit S.P.A UNCRITMM 16 CitiBank, N.A CITIITMX 17 Intesa Sanpaolo SPA Head Office BCITITMM 20 Commerzbank AG COBAITMM ITALY Industrial & Commercial Bank of China, Milan 21 Branch ICBKITMM 22 Bank of Tokyo-Mitsubishi UFJ, LTD, Milan Branch BOTKITMX Unicredit Bank AG Singapore Branch 23 (HypoVereinsBank AG Singapore Branch) BVBESGSG 24 United Overseas Bank Ltd. Head Office UOVBSGSG 25 JPMorgan Chase Bank, N.A. Singapore Branch CHASSGSG 26 SINGAPORE Bank of Tokyo-Mitsubishi UFJ, LTD, Singapore BranchBOTKSGSX Skandinaviska Enskilda Banken AB (PUBL). 27 Singapore Branch ESSESGSG 28 Mizuho Bank, Ltd. Singapore Branch MHCBSGSG 29 CitiBank, N.A. Singapore Branch CITISGSG 30 Industrial & Commercial Bank of China, Singapore BranchICBKSGSG 31 Deutsche Bank AG DEUTDEFF 32 BHF-BANK Aktiengesellschaft BHFBDEFF GERMANY 33 Landesbank Baden-Wuerttemberg SOLADEST
    [Show full text]
  • Notice of Company Split
    (Translation) February 3, 2021 Dear Sirs and Madams, Name of Company: Shiseido Company, Limited Name of Representative: Masahiko Uotani President and CEO (Representative Director) (Code No. 4911; The First Section of the Tokyo Stock Exchange) Contact: Harumoto Kitagawa Vice President Investor Relations Department (Tel: +81 3 3572 5111) Notice of Company Split (Simple Absorption-type Split) and Other Changes Accompanying the Transfer of the Personal Care Business —Aiming for Further Business Growth and Development through Joint Venture with CVC— Shiseido Company, Limited (the “Company”) has launched a fundamental business transformation positioning skin beauty as its core business category and aims to become a global leader in this field by 2030. As a part of these efforts, the Company has been continuously revisiting its business portfolio. The Company recognizes that its Personal Care business, comprising such global brands as TSUBAKI and SENKA (the “Business”), requires enhanced marketing investment to maximize its potential and foster further growth, and concludes that these goals will be best achieved under a new business model. Therefore, the Company has determined to transfer the Business and participate in its operation as a shareholder of the company which will manage the Business after the transfer. The Business will be transferred from the Company and its wholly owned subsidiaries, to be succeeded by a newly established company (the “New Company”), whose shares will be subsequently transferred to Oriental Beauty Holding Company, Limited (“OBH”), financed by funds advised by CVC Capital Partners (“CVC”) (the “Transaction”). Following the Transaction, the Company will provide cooperation aimed at further growth and development of the Business by establishing a joint venture and acting as a shareholder of the company which will operate the Business after the transfer, including the New Company and OBH.
    [Show full text]
  • 2020 Integrated Report
    Integrated Report 2020 Year ended March 31, 2020 Basic Commitment of the Toshiba Group Committed to People, Committed to the Future. At Toshiba, we commit to raising the quality of life for people around The Essence of Toshiba the world, ensuring progress that is in harmony with our planet. Our Purpose The Essence of Toshiba is the basis for the We are Toshiba. We have an unwavering drive to make and do things that lead to a better world. sustainable growth of the Toshiba Group and A planet that’s safer and cleaner. the foundation of all corporate activities. A society that’s both sustainable and dynamic. A life as comfortable as it is exciting That’s the future we believe in. We see its possibilities, and work every day to deliver answers that will bring on a brilliant new day. By combining the power of invention with our expertise and desire for a better world, we imagine things that have never been – and make them a reality. That is our potential. Working together, we inspire a belief in each other and our customers that no challenge is too great, and there’s no promise we can’t fulfill. We turn on the promise of a new day. Our Values Do the right thing We act with integrity, honesty and The Essence of Toshiba comprises three openness, doing what’s right— not what’s easy. elements: Basic Commitment of the Toshiba Group, Our Purpose, and Our Values. Look for a better way We continually s trive to f ind new and better ways, embracing change With Toshiba’s Basic Commitment kept close to as a means for progress.
    [Show full text]
  • Daiichi Sankyo Company, Limited
    [Translation] CONVOCATION NOTICE OF THE 14TH ORDINARY GENERAL MEETING OF SHAREHOLDERS For the Fiscal Year Ended March 31, 2019 Daiichi Sankyo Company, Limited *Note: This translation does not include pictures, charts etc. originally issued in the Japanese version. - 1 - [Translation] To Our Shareholders At the Daiichi Sankyo Group (“the Group”), we are proceeding with the initiatives of 4th mid- term business plan with the aim of becoming a “Global Pharma Innovator with Competitive Advantage in Oncology” as set forth in our 2025 Vision. In fiscal 2018, we made significant progress in developing new drugs in oncology area, including DS-8201, an antibody drug conjugates utilizing our proprietary technologies. In addition, we entered into a strategic collaboration agreement with AstraZeneca, which has strengths in the oncology business, for the global development and commercialization of DS-8201 in order to maximize its value. Furthermore, sales of mainstay products such as edoxaban, an anticoagulant which supports current earnings of the Group, were firm in Japan and overseas. The achievement of initial target of mid-term business plan for fiscal 2020 is expected to be delayed by two years due to failure of achievement of the plan for pain franchise business and additional investments in research and development. However, we are gaining confidence of achieving our 2025 Vision and accelerating growth in the future due to the significant improvement in the value of oncology area pipelines. We will continue to make every effort to achieve the goals of the Medium-Term Management Plan and 2025 Vision. I greatly appreciate your continued support in the future.
    [Show full text]
  • Daiichi Sankyo Group Value Report 2019
    External Evaluations (as of June 30,2019) ™ Daiichi Sankyo Group Value Report 2019 Value Daiichi Sankyo Group MSCI Japan Empowering Women Select Index THE INCLUSION OF DAIICHI SANKYO CO.,LTD. IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF DAIICHI SANKYO CO.,LTD. BY MSCI OR ANY OF ITS AFFILIATES. THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADE- MARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES. “Eruboshi” Certification Mark “Kurumin” Certification Mark Logo given to Certified Health and Productivity Management Organization (White500) This report uses FSC® certified paper, which indicates that the paper used to print this Paper report was produced from properly managed forests. 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426, Japan This report was printed using 100% Inks biodegradable printing inks from vegetable Corporate Communications Department oil. Daiichi Sankyo Group Tel: +81-3-6225-1126 CSR Department The waterless printing method used for this Value Report 2019 Tel: +81-3-6225-1067 Printing report minimized the use and release of harmful liquid wastes. https://www.daiichisankyo.com/ Printed in Japan 005_7045687911909.indd 1 2019/09/27 18:22:19 Introduction Our Mission The Core Values and Commitments serve as the criteria for business activities and In addition, we have established the DAIICHI SANKYO Group Corporate Conduct Charter . decision-making used by executive officers and employees in working to fulfill Our Mission . This charter calls on us to fulfill our social responsibilities by acting with the highest ethical Our Corporate Slogan succinctly explains the spirit of Our Mission, Core Values and standards and a good social conscience appropriate for a company engaged in business Commitments.
    [Show full text]
  • Convocation Notice of the 16Th Ordinary General Meeting of Shareholders
    [Translation] CONVOCATION NOTICE OF THE 16TH ORDINARY GENERAL MEETING OF SHAREHOLDERS For the Fiscal Year Ended March 31, 2021 Daiichi Sankyo Company, Limited *Note: This translation does not include pictures, charts etc. originally issued in the Japanese version. [Translation] To Our Shareholders We sincerely appreciate the continuous kindness of our shareholders. In addition, we would like to express our deepest sympathies to those who passed away due to COVID-19, and thank the medical personnel who are close to those who are fighting illness and are making efforts in treatment. We will continue to devote ourselves to the research and development of vaccines and therapeutic agents. Our “Purpose” is to “contribute to the enrichment of quality of life around the world.” As a pharmaceutical company with strengths in science and technology, we continuously create innovative pharmaceuticals and provide pharmaceuticals that meet diverse medical needs to provide sustainable value to society. We were able to launch the anti-cancer drug “Enhertu”, which is an antibody-drug conjugate (ADC) that utilizes our unique technology, in Japan and Europe in fiscal 2020, following the launch in the U.S. in fiscal 2019. Subsequent ADCs such as Dato-DXd and HER3-DXd are also steadily developing. Now, we have newly established our 2030 Vision of being an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society,” and have established 5-Year Business Plan (fiscal 2021 to fiscal 2025) as a plan to realize our 2025 Vision, “Global Pharma Innovator with Competitive Advantage in Oncology.” By working together as a Daiichi Sankyo Group on 5-Year Business Plan toward the 2030 Vision, we aim to solve the social issues expected of our company and increase shareholder value.
    [Show full text]
  • Shiseido CSR Website 2015
    Shiseido's Corporate Social Responsibility Back Issues 2015 Shiseido CSR [Shiseido’s Corporate Social Responsibility] Although the target period for the information included in this back number is mainly FY2014 (from April 1, 2014 to March 31, 2015 ), part of the information also includes contents prior to/after the said period. [CONTENTS] ○ What is Shiseido CSR? ··························································································· 1 ○ Top Commitment ························································································ ·········· 10 ○ Beauty ································································· ······························· 12 ● ················································ 12 ● ··········································································· 17 ● ······················································································ 19 ○ Environment ········································································································· 20 ●Environmental policy ························································································ 20 ●Environmental management ·············································································· 23 ●Responding to Environmental Risks ···································································· 24 ●Environmental targets and results ····································································· 26 ●Product initiatives ····················································································
    [Show full text]
  • Daiichi Sankyo Company, Limited
    [Translation] CONVOCATION NOTICE OF THE 6TH ORDINARY GENERAL MEETING OF SHAREHOLDERS For the Fiscal Period Ended March 31, 2011 Daiichi Sankyo Company, Limited - 1 - [Translation] (Securities Identification Code 4568) May 31, 2011 To Shareholders, Daiichi Sankyo Company, Limited Joji Nakayama, Representative Director and President & CEO 5-1, Nihonbashi Honcho 3-chome, Chuo-ku, Tokyo, Japan CONVOCATION NOTICE OF THE 6TH ORDINARY GENERAL MEETING OF SHAREHOLDERS We wish to extend our deepest sympathy to all those who have suffered hardship from the Great East Japan Earthquake that occurred in March 2011. Daiichi Sankyo Company, Limited (“the Company”) respectfully requests your attendance at the 6th Ordinary General Meeting of Shareholders (“the Meeting”), which will be held as detailed below. If you will not be able to attend the Meeting, you may exercise your voting rights through either of the methods described below, in which case we ask that you please exercise your voting rights by 17:30 (within our business hours), Friday, June 24, 2011 (Japan Time), after examining the attached reference documents. [Exercise of Voting Rights by Mail] Please indicate your approval or disapproval for the proposals on the enclosed voting form and return the form to the Company. Please note that the form must be received by the Company no later than the above-mentioned deadline. [Exercise of Voting Rights on the Internet etc.] After examining “Information on Exercise of Voting Rights, etc.” on pages 57 and 58, please vote on the Internet at the dedicated voting website (http://www.evote.jp/) no later than the above-mentioned deadline. The Company is participating in the platform for electronic exercise of voting rights for institutional investors operated by ICJ Inc.
    [Show full text]
  • Whither the Keiretsu, Japan's Business Networks? How Were They Structured? What Did They Do? Why Are They Gone?
    IRLE IRLE WORKING PAPER #188-09 September 2009 Whither the Keiretsu, Japan's Business Networks? How Were They Structured? What Did They Do? Why Are They Gone? James R. Lincoln, Masahiro Shimotani Cite as: James R. Lincoln, Masahiro Shimotani. (2009). “Whither the Keiretsu, Japan's Business Networks? How Were They Structured? What Did They Do? Why Are They Gone?” IRLE Working Paper No. 188-09. http://irle.berkeley.edu/workingpapers/188-09.pdf irle.berkeley.edu/workingpapers Institute for Research on Labor and Employment Institute for Research on Labor and Employment Working Paper Series (University of California, Berkeley) Year Paper iirwps-- Whither the Keiretsu, Japan’s Business Networks? How Were They Structured? What Did They Do? Why Are They Gone? James R. Lincoln Masahiro Shimotani University of California, Berkeley Fukui Prefectural University This paper is posted at the eScholarship Repository, University of California. http://repositories.cdlib.org/iir/iirwps/iirwps-188-09 Copyright c 2009 by the authors. WHITHER THE KEIRETSU, JAPAN’S BUSINESS NETWORKS? How were they structured? What did they do? Why are they gone? James R. Lincoln Walter A. Haas School of Business University of California, Berkeley Berkeley, CA 94720 USA ([email protected]) Masahiro Shimotani Faculty of Economics Fukui Prefectural University Fukui City, Japan ([email protected]) 1 INTRODUCTION The title of this volume and the papers that fill it concern business “groups,” a term suggesting an identifiable collection of actors (here, firms) within a clear-cut boundary. The Japanese keiretsu have been described in similar terms, yet compared to business groups in other countries the postwar keiretsu warrant the “group” label least.
    [Show full text]
  • Changes of Directors and Executive Officers
    March 22, 2021 Mizuho Financial Group, Inc. Changes of Directors and Executive Officers Mizuho Financial Group, Inc. hereby announces changes of Member of the Board of Directors and Executive Officers (including changes in their areas of responsibility, etc.) of the following entities within the Group : Mizuho Financial Group, Inc. (MHFG) Mizuho Bank, Ltd. (MHBK) Mizuho Trust & Banking Co., Ltd. (MHTB) Mizuho Securities Co., Ltd. (MHSC) Mizuho Research & Technologies, Ltd. (MHRT) 1 Contents Mizuho Financial Group, Inc. (MHFG) .......................................................................................................... 3 1. Changes of Member of the Board of Directors ..................................................................................... 3 2. Changes of Executive Officers .............................................................................................................. 3 3. Directors and Executive Officers as of April 1, 2021 .......................................................................... 5 Mizuho Bank, Ltd. (MHBK) ............................................................................................................................ 8 1. Changes of Directors and Executive Officers ...................................................................................... 8 2. Directors and Executive Officers as of April 1, 2021 ......................................................................... 12 Mizuho Trust & Banking Co., Ltd. (MHTB) ...............................................................................................
    [Show full text]
  • Western Asset Premier Institutional Liquid Reserves
    Western Asset Premier Institutional Liquid Reserves As of: Aug-31-2021 Weighted Average Maturity: 52 days Weighted Average Life: 68 days Net Assets: $9,479,393,258 % of Net Principal Amount Securities Description Rate CUSIP Value Assets Effective Maturity* Final Maturity Rule-2a-7 Category of Investment Certificate of Deposit 185,000,000 SUMITOMO MITSUI TRUST BANK LTD/ NEW YORK 0.07% 86564GQ95 185,000,000.00 1.95% 2021-09-07 2021-09-07 Certificate of Deposit 159,000,000 MUFG BANK LTD/NY 0.07% 55380TNH9 159,034,180.23 1.68% 2021-10-14 2021-10-14 Certificate of Deposit 150,000,000 STANDARD CHARTERED BANK 0.21% 85325VN30 150,003,388.50 1.58% 2022-06-08 2022-06-08 Certificate of Deposit 150,000,000 DNB NOR BANK ASA NY 0.07% 23344NFC5 149,999,958.00 1.58% 2021-09-02 2021-09-02 Certificate of Deposit 130,000,000 NATIXIS SA/NEW YORK NY 0.14% 63873QMF8 130,035,635.60 1.37% 2021-10-05 2022-01-05 Certificate of Deposit 125,000,000 MIZUHO BANK LTD/NY 0.07% 60710AXN7 125,037,973.75 1.32% 2021-11-03 2021-11-03 Certificate of Deposit 115,000,000 KBC BANK NV NY 0.06% 4823TCC27 115,000,000.00 1.21% 2021-09-07 2021-09-07 Certificate of Deposit 100,000,000 CREDIT SUISSE NEW YORK 0.23% 22552G3W8 100,025,993.00 1.06% 2022-05-27 2022-05-27 Certificate of Deposit 100,000,000 NORINCHUKIN BANK NY 0.15% 65602YJZ4 100,017,755.00 1.06% 2022-02-25 2022-02-25 Certificate of Deposit 100,000,000 BANK OF MONTREAL CHICAGO 0.19% 06367CJG3 100,014,384.00 1.06% 2022-07-22 2022-07-22 Certificate of Deposit 100,000,000 LLOYDS BANK CORP MARKETS 0.22% 53947CM70 100,010,683.00
    [Show full text]
  • Press Release
    Press Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Sunao Manabe, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Junichi Onuma, Vice President, Corporate Communications Department Telephone: +81-3-6225-1126 https://www.daiichisankyo.com Daiichi Sankyo Announces Transfer from Astellas Pharma of Three Products in Asia Tokyo, Japan (October 15, 2019) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it agreed with Astellas Pharma Inc. (hereafter, Astellas Pharma) that Astellas Pharma local subsidiaries companies in six Asian countries will transfer three products to Daiichi Sankyo. The products to be transferred and the countries where they are sold are as follows. Product Korea China Taiwan Thailand Philippines Indonesia [generic name (brand name)] Ramosetron Antiemetic ○ ○ ○ ○ (Nasea) Nicardipine Anti- ○ ○ ○ (Perdipine) hypertensive Barnidipine Anti- ○ (Oldeca) hypertensive ○ indicate the countries where the products are sold The antiemetics are expected to have synergistic effects with mirogabalin and the cancer drugs that Daiichi Sankyo is currently developing in Asia, and the two antihypertensives are expected to effectively utilize Daiichi Sankyo’s current infrastructures in combination with its cardiovascular products, such as olmesartan and edoxaban. The total net sales of Astellas Pharma's three products in fiscal year 2018 were approximately 5.0 billion yen. 1 Daiichi Sankyo will take over the rights
    [Show full text]